151 related articles for article (PubMed ID: 9748012)
1. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group.
Apfel SC; Kessler JA; Adornato BT; Litchy WJ; Sanders C; Rask CA
Neurology; 1998 Sep; 51(3):695-702. PubMed ID: 9748012
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group.
Apfel SC; Schwartz S; Adornato BT; Freeman R; Biton V; Rendell M; Vinik A; Giuliani M; Stevens JC; Barbano R; Dyck PJ
JAMA; 2000 Nov; 284(17):2215-21. PubMed ID: 11056593
[TBL] [Abstract][Full Text] [Related]
3. Peripheral neuropathy in transgenic diabetic mice: restoration of C-fiber function with human recombinant nerve growth factor.
Elias KA; Cronin MJ; Stewart TA; Carlsen RC
Diabetes; 1998 Oct; 47(10):1637-42. PubMed ID: 9753304
[TBL] [Abstract][Full Text] [Related]
4. The effect of ubiquinone in diabetic polyneuropathy: a randomized double-blind placebo-controlled study.
Hernández-Ojeda J; Cardona-Muñoz EG; Román-Pintos LM; Troyo-Sanromán R; Ortiz-Lazareno PC; Cárdenas-Meza MA; Pascoe-González S; Miranda-Díaz AG
J Diabetes Complications; 2012; 26(4):352-8. PubMed ID: 22595020
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human nerve growth factor and diabetic polyneuropathy.
Zochodne DW; Said G
Neurology; 1998 Sep; 51(3):662-3. PubMed ID: 9748004
[No Abstract] [Full Text] [Related]
6. [Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?].
Quasthoff S; Hartung HP
Nervenarzt; 2001 Jun; 72(6):456-9. PubMed ID: 11433707
[TBL] [Abstract][Full Text] [Related]
7. Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double-blind placebo-controlled study in Japan.
Sekiguchi K; Kohara N; Baba M; Komori T; Naito Y; Imai T; Satoh J; Yamaguchi Y; Hamatani T;
J Diabetes Investig; 2019 Mar; 10(2):466-474. PubMed ID: 29975462
[TBL] [Abstract][Full Text] [Related]
8. Human studies of recombinant human nerve growth factor and diabetic peripheral neuropathy.
Freeman R
Eur Neurol; 1999; 41 Suppl 1():20-6. PubMed ID: 10023125
[TBL] [Abstract][Full Text] [Related]
9. Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy.
Riggs JE
Neurology; 1999 Apr; 52(7):1517-8. PubMed ID: 10227655
[No Abstract] [Full Text] [Related]
10. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: the SYDNEY trial.
Ametov AS; Barinov A; Dyck PJ; Hermann R; Kozlova N; Litchy WJ; Low PA; Nehrdich D; Novosadova M; O'Brien PC; Reljanovic M; Samigullin R; Schuette K; Strokov I; Tritschler HJ; Wessel K; Yakhno N; Ziegler D;
Diabetes Care; 2003 Mar; 26(3):770-6. PubMed ID: 12610036
[TBL] [Abstract][Full Text] [Related]
11. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy - a clinical and neurophysiological study.
Fagius J; Jameson S
J Neurol Neurosurg Psychiatry; 1981 Nov; 44(11):991-1001. PubMed ID: 6801211
[TBL] [Abstract][Full Text] [Related]
12. Biological actions of nerve growth factor in the peripheral nervous system.
Rask CA
Eur Neurol; 1999; 41 Suppl 1():14-9. PubMed ID: 10023124
[TBL] [Abstract][Full Text] [Related]
13. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans.
Dyck PJ; Peroutka S; Rask C; Burton E; Baker MK; Lehman KA; Gillen DA; Hokanson JL; O'Brien PC
Neurology; 1997 Feb; 48(2):501-5. PubMed ID: 9040746
[TBL] [Abstract][Full Text] [Related]
14. A double-blind placebo-controlled clinical trial of recombinant human brain-derived neurotrophic factor (rhBDNF) in diabetic polyneuropathy.
Wellmer A; Misra VP; Sharief MK; Kopelman PG; Anand P
J Peripher Nerv Syst; 2001 Dec; 6(4):204-10. PubMed ID: 11800042
[TBL] [Abstract][Full Text] [Related]
15. Topical Citrullus colocynthis (bitter apple) extract oil in painful diabetic neuropathy: A double-blind randomized placebo-controlled clinical trial.
Heydari M; Homayouni K; Hashempur MH; Shams M
J Diabetes; 2016 Mar; 8(2):246-52. PubMed ID: 25800045
[TBL] [Abstract][Full Text] [Related]
16. Treatment of diabetic polyneuropathy with the neurotrophic peptide ORG 2766.
Valk GD; Kappelle AC; Tjon-A-Tsien AM; Bravenboer B; Bakker K; Michels RP; Groenhout CM; Bertelsmann FW
J Neurol; 1996 Mar; 243(3):257-63. PubMed ID: 8936356
[TBL] [Abstract][Full Text] [Related]
17. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term, randomised, double-blind, placebo-controlled study.
De Grandis D; Minardi C
Drugs R D; 2002; 3(4):223-31. PubMed ID: 12455197
[TBL] [Abstract][Full Text] [Related]
18. Cilostazol: a pilot study on safety and clinical efficacy in neuropathies of diabetes mellitus type 2 (ASCEND).
Rosales RL; Santos MM; Mercado-Asis LB
Angiology; 2011 Nov; 62(8):625-35. PubMed ID: 21733952
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?
Apfel SC
Int Rev Neurobiol; 2002; 50():393-413. PubMed ID: 12198818
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of ranirestat in patients with mild-to-moderate diabetic sensorimotor polyneuropathy.
Polydefkis M; Arezzo J; Nash M; Bril V; Shaibani A; Gordon RJ; Bradshaw KL; Junor RW;
J Peripher Nerv Syst; 2015 Dec; 20(4):363-71. PubMed ID: 26313450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
